Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Semi-annual Business Results
December 13, 2004
- MEDICAL DEVICE NEWS IN BRIEF
December 13, 2004
- 8 Drugs Including PegIntron to Be Added to NHI List
December 13, 2004
- Astellas "1st Step Toward Becoming a Global Mega-pharma": Dr Aoki
December 13, 2004
- Combination Therapies to Be Approved for 5 Types of Cancer
December 13, 2004
- Aredia Approved for Osteoclastic Bone Metastasis of Breast Cancer
December 13, 2004
- Final ICH Agreement Reached on Pharmacovigilance Planning: Korosho
December 13, 2004
- JPMA to Present Proposals on NHI Price System Next Year
December 6, 2004
- Nichiban: Strong Increase in Profits Despite Flat Sales
December 6, 2004
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
December 6, 2004
- FJPWA SEMINAR
December 6, 2004
- Biofermin: Sales Up 1.1% to \3,565 Mil.
December 6, 2004
- BULLETIN
December 6, 2004
- BUSINESS NEWS IN BRIEF
December 6, 2004
- Nissan Chemical: Pharma Sales, Profits Down Sharply
December 6, 2004
- OTC NEWS IN BRIEF
December 6, 2004
- Semi-annual Business Results
December 6, 2004
- Annual Business Results
December 6, 2004
- MEDICAL DEVICE NEWS IN BRIEF
December 6, 2004
- Sales of 26 Leading JPMA Firms Up 0.5%
December 6, 2004
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…